{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:19:53Z","timestamp":1791073193867,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.antiviral.2013.09.020","type":"journal-article","created":{"date-parts":[[2013,9,30]],"date-time":"2013-09-30T17:27:28Z","timestamp":1380562048000},"page":"555-561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Host-targeting agents in the treatment of hepatitis C: A beginning and an end?"],"prefix":"10.1016","volume":"100","author":[{"given":"James M.","family":"Baugh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Garcia-Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe A.","family":"Gallay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2013.09.020_b0005","first-page":"1067A","article-title":"New cyclophilin inhibitors unrelated to cyclosporine potently inhibit HCV replication and revert HCV-induced mitochondrial dysfunction","volume":"56","author":"Ahmed-Belkacem","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0010","doi-asserted-by":"crossref","first-page":"S553","DOI":"10.1016\/S0168-8278(12)61417-2","article-title":"Alisporivir (Alv) plus peg-interferon\/ribavirin (Pr) in Hcv G1 treatment-experienced patients achieves primary endpoint with superior efficacy at treatment week 12 compared to retreatment with Pr","volume":"56","author":"Alberti","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0015","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature02871","article-title":"The functions of animal microRNAs","volume":"431","author":"Ambros","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2013.09.020_b0020","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1515\/hsz-2012-0151","article-title":"Cyclophilin involvement in the replication of hepatitis C virus and other viruses","volume":"393","author":"Baugh","year":"2012","journal-title":"Biological Chemistry"},{"key":"10.1016\/j.antiviral.2013.09.020_b0025","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1073\/pnas.0902693106","article-title":"Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication","volume":"106","author":"Berger","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.antiviral.2013.09.020_b0030","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3851\/IMP2023","article-title":"Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7","volume":"17","author":"Boonstra","year":"2012","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.antiviral.2013.09.020_b0035","first-page":"433","article-title":"History of the discovery of cyclosporin and of its early pharmacological development","volume":"114","author":"Borel","year":"2002","journal-title":"Wiener klinische Wochenschrift"},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2013.09.020_b0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1478-3231.2011.02701.x","article-title":"New targets for antiviral therapy of chronic hepatitis C","volume":"32","author":"Buhler","year":"2012","journal-title":"Liver international: Official Journal of the International Association for the Study of the Liver"},{"key":"10.1016\/j.antiviral.2013.09.020_b0045","doi-asserted-by":"crossref","first-page":"16998","DOI":"10.1074\/jbc.M109.007625","article-title":"The isomerase active site of cyclophilin A is critical for hepatitis C virus replication","volume":"284","author":"Chatterji","year":"2009","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.antiviral.2013.09.020_b0050","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jhep.2010.01.041","article-title":"HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors","volume":"53","author":"Chatterji","year":"2010","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0055","doi-asserted-by":"crossref","first-page":"e13687","DOI":"10.1371\/journal.pone.0013687","article-title":"DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A","volume":"5","author":"Coelmont","year":"2010","journal-title":"Plos One"},{"key":"10.1016\/j.antiviral.2013.09.020_b0060","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1089\/jir.2010.0078","article-title":"Interferon-lambda: a new addition to an old family","volume":"30","author":"Donnelly","year":"2010","journal-title":"Journal of Interferon and Cytokine Research"},{"key":"10.1016\/j.antiviral.2013.09.020_b0065","first-page":"1066A","article-title":"TVB-2640, a novel anti-HCV agent, safely causes sustained host-target inhibition in vivo","volume":"56","author":"Evanchik","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0070","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/nsmb.2296","article-title":"The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC","volume":"19","author":"Fabian","year":"2012","journal-title":"Nature Structural and Molecular Biology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0075","doi-asserted-by":"crossref","first-page":"e9815","DOI":"10.1371\/journal.pone.0009815","article-title":"Cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A","volume":"5","author":"Fernandes","year":"2010","journal-title":"Plos One"},{"key":"10.1016\/j.antiviral.2013.09.020_b0080","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/hep.22835","article-title":"The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients","volume":"49","author":"Flisiak","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0085","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/hep.22131","article-title":"The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus","volume":"47","author":"Flisiak","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(11)60006-8","article-title":"Once Daily Alisporivir (Deb025) Plus Pegifnalfa2a\/Ribavirin Results in Superior Sustained Virologic Response (Svr24) in Chronic Hepatitis C Genotype 1 Treatment Naive Patients","volume":"54","author":"Flisiak","year":"2011","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0095","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1128\/AAC.02239-12","article-title":"Combinations of Lambda Interferon with Direct-Acting Antiviral Agents Are Highly Efficient in Suppressing Hepatitis C Virus Replication","volume":"57","author":"Friborg","year":"2013","journal-title":"Antimicrobial Agents and Chemotheraphy"},{"key":"10.1016\/j.antiviral.2013.09.020_b0100","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.virol.2013.07.005","article-title":"Isolation and characterization of interferon lambda-resistant hepatitis C virus replicon cell lines","volume":"444","author":"Friborg","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0105","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/DDDT.S30946","article-title":"Profile of alisporivir and its potential in the treatment of hepatitis C","volume":"7","author":"Gallay","year":"2013","journal-title":"Drug Design, Development and Therapy"},{"key":"10.1016\/j.antiviral.2013.09.020_b0110","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1073\/pnas.1220841110","article-title":"MiR-122 is more than a shield for the hepatitis C virus genome","volume":"110","author":"Garcia-Sastre","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.antiviral.2013.09.020_b0115","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nrm2104","article-title":"The highways and byways of mRNA decay","volume":"8","author":"Garneau","year":"2007","journal-title":"Nature Reviews. Molecular Cell Biology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0120","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"American Association for the Study of Liver, D., Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0125","unstructured":"Gilead Sciences. Gilead Reports Interim Data from Phase 2 LONESTAR Study. Press Release, May 2, 2013."},{"key":"10.1016\/j.antiviral.2013.09.020_b0130","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.bbrc.2006.03.059","article-title":"Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811","volume":"343","author":"Goto","year":"2006","journal-title":"Biochemical and Biophysics Research Communication"},{"key":"10.1016\/j.antiviral.2013.09.020_b0135","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1128\/AAC.01627-10","article-title":"Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family","volume":"55","author":"Gregory","year":"2011","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.antiviral.2013.09.020_b0140","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/mt.2012.173","article-title":"All for one, one for all: new combinatorial RNAi therapies combat hepatitis C virus evolution","volume":"20","author":"Grimm","year":"2012","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"key":"10.1016\/j.antiviral.2013.09.020_b0145","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1074\/jbc.M809244200","article-title":"Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis\/trans isomerase activity of cyclophilins A and B","volume":"284","author":"Hanoulle","year":"2009","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.antiviral.2013.09.020_b0150","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nri3463","article-title":"25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end","volume":"13","author":"Heim","year":"2013","journal-title":"Nature Reviews Immunology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0155","article-title":"A Unique Therapy for Hcv Inhibits Microrna-122 in Humans and Results in Hcv Rna Suppression in Chronically Infected Chimpanzees: Results from Primate and First-in-Human Studies","volume":"50","author":"Hildebrandt-Eriksen","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0160","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jhep.2012.02.024","article-title":"The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection","volume":"57","author":"Hopkins","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0165","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1128\/AAC.00660-09","article-title":"SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro","volume":"54","author":"Hopkins","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.antiviral.2013.09.020_b0170","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1073\/pnas.0700760104","article-title":"Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins","volume":"104","author":"Huang","year":"2007","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.antiviral.2013.09.020_b0175","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.1128\/JVI.02526-12","article-title":"Hepatitis C Virus Replication Is Modulated by the Interaction of Nonstructural Protein NS5B and Fatty Acid Synthase","volume":"87","author":"Huang","year":"2013","journal-title":"Journal of Virology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0180","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00535-002-1104-5","article-title":"Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial","volume":"38","author":"Inoue","year":"2003","journal-title":"Journal of Gastroenterology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0185","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.transproceed.2004.11.041","article-title":"Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease","volume":"37","author":"Inoue","year":"2005","journal-title":"Transplantation Proceedings"},{"key":"10.1016\/j.antiviral.2013.09.020_b0190","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1128\/JVI.80.9.4510-4520.2006","article-title":"Diverse effects of cyclosporine on hepatitis C virus strain replication","volume":"80","author":"Ishii","year":"2006","journal-title":"Journal of Virology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0195","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV infection by targeting microRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.antiviral.2013.09.020_b0200","article-title":"EDP-546, a potent and novel cyclophilin inhibitor with favorable preclinical pharmacokinetic and safety profiles","volume":"56","author":"Jiang","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0205","doi-asserted-by":"crossref","DOI":"10.1038\/nbt.1604","article-title":"Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system","volume":"28","author":"Jones","year":"2010","journal-title":"Nature Biotechnology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0210","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1126\/science.1113329","article-title":"Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA","volume":"309","author":"Jopling","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2013.09.020_b0215","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1073\/pnas.0409834102","article-title":"Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids","volume":"102","author":"Kapadia","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.antiviral.2013.09.020_b0220","doi-asserted-by":"crossref","first-page":"9483","DOI":"10.1073\/pnas.88.21.9483","article-title":"Crystal structure of recombinant human T-cell cyclophilin A at 2.5 A resolution","volume":"88","author":"Ke","year":"1991","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.antiviral.2013.09.020_b0225","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1517\/13543784.16.11.1817","article-title":"Fatty acid synthase inhibitors: new directions for oncology","volume":"16","author":"Kridel","year":"2007","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.antiviral.2013.09.020_b0230","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jhep.2012.02.018","article-title":"Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice","volume":"57","author":"Lacek","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0235","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1126\/science.1178178","article-title":"Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection","volume":"327","author":"Lanford","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2013.09.020_b0240","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","article-title":"Hepatitis C virus infection","volume":"345","author":"Lauer","year":"2001","journal-title":"The New England Journal of Medicine"},{"issue":"Suppl 1","key":"10.1016\/j.antiviral.2013.09.020_b0245","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","article-title":"The global burden of hepatitis C","volume":"29","author":"Lavanchy","year":"2009","journal-title":"Liver International: Official Journal of the International Association for the Study of the Liver"},{"issue":"3","key":"10.1016\/j.antiviral.2013.09.020_b0405","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.antiviral.2011.01.003","article-title":"Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy","volume":"89","author":"Lawitz","year":"2011","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2013.09.020_b0250","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1073\/pnas.1213515110","article-title":"Competing and noncompeting activities of miR-122 and the 5\u2019 exonuclease Xrn1 in regulation of hepatitis C virus replication","volume":"110","author":"Li","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.antiviral.2013.09.020_b0255","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1073\/pnas.1016606108","article-title":"MicroRNA-122 antagonism against hepatitis C virus genotypes 1\u20136 and reduced efficacy by host RNA insertion or mutations in the HCV 5\u2019 UTR","volume":"108","author":"Li","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.antiviral.2013.09.020_b0260","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1056\/NEJMe1301348","article-title":"Micromanaging hepatitis C virus","volume":"368","author":"Lieberman","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.antiviral.2013.09.020_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2013.03.020","article-title":"Curing a viral infection by targeting the host: the example of cyclophilin inhibitors","author":"Lin","year":"2013","journal-title":"Antiviral research"},{"key":"10.1016\/j.antiviral.2013.09.020_b0270","doi-asserted-by":"crossref","first-page":"6554","DOI":"10.1128\/JVI.02550-08","article-title":"Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex","volume":"83","author":"Liu","year":"2009","journal-title":"Journal of Virology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0275","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1128\/AAC.00310-06","article-title":"NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon","volume":"50","author":"Ma","year":"2006","journal-title":"Antimicrobial Agents and Chemotherpy"},{"key":"10.1016\/j.antiviral.2013.09.020_b0280","doi-asserted-by":"crossref","first-page":"e1000198","DOI":"10.1371\/journal.pmed.1000198","article-title":"The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis","volume":"6","author":"Magiorkinis","year":"2009","journal-title":"PLoS Medicine"},{"key":"10.1016\/j.antiviral.2013.09.020_b0285","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1161\/ATVBAHA.109.191320","article-title":"Increased HDL cholesterol and ApoA-I in humans and mice treated with a novel SR-BI inhibitor","volume":"29","author":"Masson","year":"2009","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(12)60853-8","article-title":"Bc556, a potent, pan-genotypic, high barrier to resistance, second generation cyclophilin inhibitor for treatment of chronic Hcv infection","volume":"56","author":"Moss","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0295","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/hep.23743","article-title":"Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection","volume":"52","author":"Muir","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0300","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bbrc.2003.11.080","article-title":"Specific inhibition of hepatitis C virus replication by cyclosporin A","volume":"313","author":"Nakagawa","year":"2004","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.antiviral.2013.09.020_b0305","doi-asserted-by":"crossref","unstructured":"Owens CM, R.M., Polemeropoulos A, Long J, Wang G, Jiang L, Or YS 2013. Cyclophilin Inhibitor EDP-546 is a Potential Cornerstone Drug for Use in Combination with NS5A and Protease Inhibitors Due to its High Barrier to HCV Resistance. Cyclophilin Inhibitor EDP-546 is a Potential Cornerstone Drug for Use in Combination with NS5A and Protease Inhibitors Due to its High Barrier to HCV Resistance, 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013), Amsterdam. Abstract 1213.","DOI":"10.1016\/S0168-8278(13)61214-3"},{"key":"10.1016\/j.antiviral.2013.09.020_b0310","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/hep.21102","article-title":"The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro","volume":"43","author":"Paeshuyse","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0315","first-page":"309A","article-title":"Alisporivir plus Ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)-free or IFN-add-on regimen in treatment-naive patients with HCV GT2 or GT3: final results from VITAL-1 study","volume":"56","author":"Pawlotsky","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0320","doi-asserted-by":"crossref","first-page":"7593","DOI":"10.1128\/JVI.02824-12","article-title":"Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype","volume":"87","author":"Perales","year":"2013","journal-title":"Journal of virology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0325","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(03)15109-4","article-title":"Viral hepatitis C","volume":"362","author":"Poynard","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2013.09.020_b0330","doi-asserted-by":"crossref","first-page":"12884","DOI":"10.1073\/pnas.0704894104","article-title":"Cellular cofactors affecting hepatitis C virus infection and replication","volume":"104","author":"Randall","year":"2007","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.antiviral.2013.09.020_b0335","doi-asserted-by":"crossref","unstructured":"Reiss, S., Harak, C., Romero-Brey, I., Radujkovic, D., Klein, R., Ruggieri, A., Rebhan, I., Bartenschlager, R., Lohmann, V., 2013. The Lipid Kinase Phosphatidylinositol-4 Kinase III Alpha Regulates the Phosphorylation Status of Hepatitis C Virus NS5A. Plos Pathog 9.","DOI":"10.1371\/journal.ppat.1003359"},{"key":"10.1016\/j.antiviral.2013.09.020_b0340","article-title":"Imo-2125, a Tlr9 Agonist, Induces Immune Responses Which Correlate with Reductions in Viral Load in Null Responder Hcv Patients","volume":"52","author":"Rodriguez-Torres","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0345","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm.3248","article-title":"Understanding the hepatitis C virus life cycle paves the way for highly effective therapies","volume":"19","author":"Scheel","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.antiviral.2013.09.020_b0350","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1073\/pnas.1112263109","article-title":"Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex","volume":"109","author":"Shimakami","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.antiviral.2013.09.020_b0355","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.immuni.2006.08.007","article-title":"Type I interferons in host defense","volume":"25","author":"Stetson","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.antiviral.2013.09.020_b0360","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jhep.2010.06.024","article-title":"Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors","volume":"54","author":"Syder","year":"2011","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0365","doi-asserted-by":"crossref","first-page":"11595","DOI":"10.1128\/JVI.01320-12","article-title":"Evaluation of Phosphatidylinositol-4-Kinase III alpha as a Hepatitis C Virus Drug Target","volume":"86","author":"Vaillancourt","year":"2012","journal-title":"Journal of virology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0370","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jviromet.2010.01.020","article-title":"The use of AlphaLISA technology to detect interaction between hepatitis C virus-encoded NS5A and cyclophilin A","volume":"165","author":"Waller","year":"2010","journal-title":"J Virol Methods"},{"key":"10.1016\/j.antiviral.2013.09.020_b0375","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1053\/jhep.2003.50449","article-title":"Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes","volume":"38","author":"Watashi","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0380","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1099\/vir.0.006700-0","article-title":"CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells","volume":"90","author":"Witteveldt","year":"2009","journal-title":"J Gen Virol"},{"key":"10.1016\/j.antiviral.2013.09.020_b0385","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/hep.22508","article-title":"Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production","volume":"48","author":"Yang","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0390","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1016\/S0168-8278(11)61362-7","article-title":"PEGYLATED INTERFERON-LAMBDA (PEGIFN-lambda) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFN alpha-2A IN HCV PATIENTS (G1\/2\/3\/4): EMERGE PHASE IIB THROUGH WEEK 12","volume":"54","author":"Zeuzem","year":"2011","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.antiviral.2013.09.020_b0395","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/infdis\/jir802","article-title":"Evaluation of ITX 5061, a Scavenger Receptor B1 Antagonist: Resistance Selection and Activity in Combination With Other Hepatitis C Virus Antivirals","volume":"205","author":"Zhu","year":"2012","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.antiviral.2013.09.020_b0400","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1002\/pro.5560010903","article-title":"Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition","volume":"1","author":"Zydowsky","year":"1992","journal-title":"Protein Science"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354213002684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354213002684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T04:28:18Z","timestamp":1564201698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354213002684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0166354213002684"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2013.09.020","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Host-targeting agents in the treatment of hepatitis C: A beginning and an end?","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2013.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}